PDF(Pubmed)
Abstract：
UNASSIGNED: Short-acting β2-agonists (SABA) overuse is associated with asthma morbidity and mortality. The SABA use IN Asthma (SABINA) program aimed to describe the global use of SABA in patients with asthma. SABINA III study was a cross-sectional study covering 24 countries.
UNASSIGNED: We performed statistical analysis of the Russian population (618 patients recruited in 12 centers) from the SABINA III study. In this study in patients aged ≥12 years, data on disease characteristics and asthma treatments were collected using real-time electronic case report forms. Patients were classified by asthma severity and control according to the 2017 GINA. All variables (asthma severity and control, number of severe exacerbations, SABA and other medications use) were analyzed descriptively only, no hypothesis was tested.
UNASSIGNED: Majority of the study population consisted of patients with moderate/severe asthma (78.5%), while mild asthma was seen in 21.5%. Asthma was uncontrolled in 36.1% of patients and partly controlled in 33.5%. More than 80% of patients were treated with ICS/LABA fixed-dose combination. Almost half of all patients (47.0%) had at least 1 severe exacerbation in the previous 12 months. SABA over-prescription (≥3 canisters per year) was seen in 37% of patients. The frequency of SABA over-prescription was similar in patients with mild (35%) and moderate/severe (38%) asthma. SABA was purchased over-the-counter (OTC) in the past 12 months by 30.1% of all patients, and 14% purchased ≥3 canisters of SABA per year. About 91% of patients who purchased SABA OTC already received prescriptions for SABA, of whom 59% were prescribed ≥3 canisters per year.
UNASSIGNED: Russia is seeing very high level of SABA over-prescription. This is potentially associated with poor asthma control and frequent severe exacerbations. Over-prescription may serve as the main cause for SABA overuse in Russia. To reduce SABA overuse and improve overall asthma control in Russia, it is necessary to educate not just the patients but also the doctors, while actively implementing up-to-date asthma treatments.
UNASSIGNED: We performed statistical analysis of the Russian population (618 patients recruited in 12 centers) from the SABINA III study. In this study in patients aged ≥12 years, data on disease characteristics and asthma treatments were collected using real-time electronic case report forms. Patients were classified by asthma severity and control according to the 2017 GINA. All variables (asthma severity and control, number of severe exacerbations, SABA and other medications use) were analyzed descriptively only, no hypothesis was tested.
UNASSIGNED: Majority of the study population consisted of patients with moderate/severe asthma (78.5%), while mild asthma was seen in 21.5%. Asthma was uncontrolled in 36.1% of patients and partly controlled in 33.5%. More than 80% of patients were treated with ICS/LABA fixed-dose combination. Almost half of all patients (47.0%) had at least 1 severe exacerbation in the previous 12 months. SABA over-prescription (≥3 canisters per year) was seen in 37% of patients. The frequency of SABA over-prescription was similar in patients with mild (35%) and moderate/severe (38%) asthma. SABA was purchased over-the-counter (OTC) in the past 12 months by 30.1% of all patients, and 14% purchased ≥3 canisters of SABA per year. About 91% of patients who purchased SABA OTC already received prescriptions for SABA, of whom 59% were prescribed ≥3 canisters per year.
UNASSIGNED: Russia is seeing very high level of SABA over-prescription. This is potentially associated with poor asthma control and frequent severe exacerbations. Over-prescription may serve as the main cause for SABA overuse in Russia. To reduce SABA overuse and improve overall asthma control in Russia, it is necessary to educate not just the patients but also the doctors, while actively implementing up-to-date asthma treatments.
摘要：
未经证实：短效β2-激动剂(SABA)过度使用与哮喘发病率和死亡率相关。SABA在哮喘中的使用（SABINA）计划旨在描述SABA在哮喘患者中的全球使用情况。SABINAIII研究是一项涵盖24个国家的横断面研究。
UNASSIGNED：我们对来自SABINAIII研究的俄罗斯人群（在12个中心招募的618名患者）进行了统计分析。在这项研究中，年龄≥12岁的患者，使用实时电子病例报告表收集有关疾病特征和哮喘治疗的数据.根据2017年GINA，按哮喘严重程度和控制对患者进行分类。所有变量（哮喘严重程度和控制，严重加重的次数，SABA和其他药物的使用)仅进行描述性分析，没有假设被检验。
未经评估：大多数研究人群包括中度/重度哮喘患者（78.5%），而轻度哮喘的发生率为21.5%。36.1％的患者未控制哮喘，33.5％的患者部分控制哮喘。超过80%的患者接受ICS/LABA固定剂量组合治疗。在过去的12个月中，几乎所有患者中的一半（47.0％）至少有1次严重加重。在37％的患者中发现SABA过度处方（每年≥3个罐）。在轻度（35％）和中度/重度（38％）哮喘患者中，SABA过度处方的频率相似。在过去的12个月中，30.1%的患者非处方药(OTC)购买了SABA，14%每年购买≥3个SABA罐。购买SABAOTC的患者中约有91％已经接受了SABA的处方，其中59%的人每年处方≥3个毒气罐。
UNASSIGNED：俄罗斯看到SABA过量处方的水平非常高。这可能与哮喘控制不佳和频繁的严重恶化有关。过度处方可能是俄罗斯SABA过度使用的主要原因。为了减少SABA过度使用并改善俄罗斯的整体哮喘控制，不仅要教育病人，还要教育医生，同时积极实施最新的哮喘治疗。
UNASSIGNED：我们对来自SABINAIII研究的俄罗斯人群（在12个中心招募的618名患者）进行了统计分析。在这项研究中，年龄≥12岁的患者，使用实时电子病例报告表收集有关疾病特征和哮喘治疗的数据.根据2017年GINA，按哮喘严重程度和控制对患者进行分类。所有变量（哮喘严重程度和控制，严重加重的次数，SABA和其他药物的使用)仅进行描述性分析，没有假设被检验。
未经评估：大多数研究人群包括中度/重度哮喘患者（78.5%），而轻度哮喘的发生率为21.5%。36.1％的患者未控制哮喘，33.5％的患者部分控制哮喘。超过80%的患者接受ICS/LABA固定剂量组合治疗。在过去的12个月中，几乎所有患者中的一半（47.0％）至少有1次严重加重。在37％的患者中发现SABA过度处方（每年≥3个罐）。在轻度（35％）和中度/重度（38％）哮喘患者中，SABA过度处方的频率相似。在过去的12个月中，30.1%的患者非处方药(OTC)购买了SABA，14%每年购买≥3个SABA罐。购买SABAOTC的患者中约有91％已经接受了SABA的处方，其中59%的人每年处方≥3个毒气罐。
UNASSIGNED：俄罗斯看到SABA过量处方的水平非常高。这可能与哮喘控制不佳和频繁的严重恶化有关。过度处方可能是俄罗斯SABA过度使用的主要原因。为了减少SABA过度使用并改善俄罗斯的整体哮喘控制，不仅要教育病人，还要教育医生，同时积极实施最新的哮喘治疗。
